Elevated SIRT1 in liver cancer stem cells (CSCs) correlates with poor prognosis; its inhibition induces CSC senescence via p53‐p21/p16 pathways, reducing tumorigenicity and enhancing chemosensitivity [66]. Here, TP53 is linked to liver cancer.